Bart S. Hendriks

3.0k total citations
64 papers, 2.3k citations indexed

About

Bart S. Hendriks is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Bart S. Hendriks has authored 64 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 28 papers in Molecular Biology and 25 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Bart S. Hendriks's work include HER2/EGFR in Cancer Research (18 papers), Monoclonal and Polyclonal Antibodies Research (18 papers) and Radiopharmaceutical Chemistry and Applications (13 papers). Bart S. Hendriks is often cited by papers focused on HER2/EGFR in Cancer Research (18 papers), Monoclonal and Polyclonal Antibodies Research (18 papers) and Radiopharmaceutical Chemistry and Applications (13 papers). Bart S. Hendriks collaborates with scholars based in United States, Canada and Switzerland. Bart S. Hendriks's co-authors include Douglas A. Lauffenburger, H Wiley, Thomas J. Wickham, Elena Geretti, Lee K. Opresko, Shannon C. Leonard, Helen Lee, Daniel F. Gaddy, Christopher W. Espelin and David de Graaf and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Bioinformatics.

In The Last Decade

Bart S. Hendriks

62 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bart S. Hendriks United States	26	1.1k	785	706	610	580	64	2.3k
Lianglin Zhang United States	24	1.4k 1.3×	539 0.7×	899 1.3×	755 1.2×	365 0.6×	42	2.8k
Qichun Wei China	30	1.2k 1.1×	903 1.2×	293 0.4×	523 0.9×	423 0.7×	138	3.2k
Iontcho R. Vlahov United States	29	1.5k 1.3×	664 0.8×	438 0.6×	279 0.5×	466 0.8×	53	2.8k
Vuong Trieu United States	23	1.2k 1.1×	2.0k 2.5×	969 1.4×	565 0.9×	194 0.3×	92	4.1k
Hilary Shmeeda Israel	27	1.7k 1.5×	669 0.9×	2.0k 2.9×	1.3k 2.1×	379 0.7×	42	3.6k
Henk J. Broxterman Netherlands	26	1.4k 1.3×	1.3k 1.6×	342 0.5×	268 0.4×	132 0.2×	51	2.8k
Steven D. Shnyder United Kingdom	30	1.4k 1.3×	712 0.9×	138 0.2×	224 0.4×	148 0.3×	98	2.5k
Jiang Yang United States	19	1.3k 1.2×	708 0.9×	433 0.6×	392 0.6×	104 0.2×	45	2.7k
Lucia Viganò Italy	23	1.3k 1.2×	1.4k 1.8×	248 0.4×	249 0.4×	92 0.2×	38	2.9k
David B. Darr United States	25	1.4k 1.3×	937 1.2×	336 0.5×	300 0.5×	64 0.1×	49	2.7k

Countries citing papers authored by Bart S. Hendriks

Since Specialization

Citations

This map shows the geographic impact of Bart S. Hendriks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bart S. Hendriks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bart S. Hendriks more than expected).

Fields of papers citing papers by Bart S. Hendriks

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bart S. Hendriks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bart S. Hendriks. The network helps show where Bart S. Hendriks may publish in the future.

Co-authorship network of co-authors of Bart S. Hendriks

This figure shows the co-authorship network connecting the top 25 collaborators of Bart S. Hendriks. A scholar is included among the top collaborators of Bart S. Hendriks based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bart S. Hendriks. Bart S. Hendriks is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Münster, Pamela N., Ian E. Krop, Patricia LoRusso, et al.. (2018). Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study. British Journal of Cancer. 119(9). 1086–1093. 95 indexed citations

Mohammad, Afroz S., Jessica I. Griffith, Chris E. Adkins, et al.. (2018). Liposomal Irinotecan Accumulates in Metastatic Lesions, Crosses the Blood-Tumor Barrier (BTB), and Prolongs Survival in an Experimental Model of Brain Metastases of Triple Negative Breast Cancer. Pharmaceutical Research. 35(2). 31–31. 54 indexed citations

Ramanathan, Ramesh K., Ronald L. Korn, Natarajan Raghunand, et al.. (2017). Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study. Clinical Cancer Research. 23(14). 3638–3648. 134 indexed citations

Blocker, Stephanie J., Kirk Douglas, Lisa Polin, et al.. (2017). Liposomal ⁶⁴Cu-PET Imaging of Anti-VEGF Drug Effects on Liposomal Delivery to Colon Cancer Xenografts. Theranostics. 7(17). 4229–4239. 17 indexed citations

Leonard, Shannon C., Helen Lee, Daniel F. Gaddy, et al.. (2017). Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer. Anti-Cancer Drugs. 28(10). 1086–1096. 25 indexed citations

Espelin, Christopher W., Shannon C. Leonard, Elena Geretti, Thomas J. Wickham, & Bart S. Hendriks. (2016). Dual HER2 Targeting with Trastuzumab and Liposomal-Encapsulated Doxorubicin (MM-302) Demonstrates Synergistic Antitumor Activity in Breast and Gastric Cancer. Cancer Research. 76(6). 1517–1527. 96 indexed citations

Gaddy, Daniel F., Helen Lee, Jinzi Zheng, et al.. (2015). Whole-body organ-level and kidney micro-dosimetric evaluations of 64Cu-loaded HER2/ErbB2-targeted liposomal doxorubicin (64Cu-MM-302) in rodents and primates. EJNMMI Research. 5(1). 24–24. 15 indexed citations

Hendriks, Bart S., Anthony F. Shields, Barry A. Siegel, et al.. (2014). PET/CT Imaging of 64CU-Labelled HER2 Liposomal Doxorubicin (64CU-MM-302) Quantifies Variability of Liposomal Drug Delivery to Diverse Tumor Lesions in HER2-Positive Breast Cancer Patients. Annals of Oncology. 25. i19–i19. 10 indexed citations

Onsum, Matthew, Elena Geretti, Violette Paragas, et al.. (2013). Single-Cell Quantitative HER2 Measurement Identifies Heterogeneity and Distinct Subgroups within Traditionally Defined HER2-Positive Patients. American Journal Of Pathology. 183(5). 1446–1460. 72 indexed citations

10.

Reynolds, Joseph G., Elena Geretti, Bart S. Hendriks, et al.. (2012). HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity. Toxicology and Applied Pharmacology. 262(1). 1–10. 93 indexed citations

11.

Böttcher‐Haberzeth, Sophie, Thomas Biedermann, Luca Pontiggia, et al.. (2012). Human Eccrine Sweat Gland Cells Turn into Melanin-Uptaking Keratinocytes in Dermo-Epidermal Skin Substitutes. Journal of Investigative Dermatology. 133(2). 316–324. 36 indexed citations

12.

Cosgrove, Benjamin D., Leonidas G. Alexopoulos, Bart S. Hendriks, et al.. (2010). Cytokine-associated drug toxicity in human hepatocytes is associated with signaling network dysregulation. Molecular BioSystems. 6(7). 1195–1206. 2 indexed citations

13.

Espelin, Christopher W., et al.. (2010). Elevated GM-CSF and IL-1β levels compromise the ability of p38MAPKinhibitors to modulate TNFα levels in the human monocytic/macrophage U937 cell line. Molecular BioSystems. 6(10). 1956–1972. 10 indexed citations

14.

Hendriks, Bart S.. (2010). Functional pathway pharmacology: chemical tools, pathway knowledge and mechanistic model-based interpretation of experimental data. Current Opinion in Chemical Biology. 14(4). 489–497. 7 indexed citations

15.

Hendriks, Bart S., Benjamin D. Cosgrove, Leonidas G. Alexopoulos, et al.. (2009). Cytokine-associated drug toxicity in human hepatocytes is associated signaling network dysregulation. DSpace@MIT (Massachusetts Institute of Technology). 44 indexed citations

16.

Cosgrove, Benjamin D., Bracken M. King, Leonidas G. Alexopoulos, et al.. (2009). Synergistic drug–cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity. Toxicology and Applied Pharmacology. 237(3). 317–330. 109 indexed citations

17.

Xu, Jinghai J., Bart S. Hendriks, Jie Zhao, & David de Graaf. (2008). Multiple effects of acetaminophen and p38 inhibitors: Towards pathway toxicology. FEBS Letters. 582(8). 1276–1282. 75 indexed citations

18.

Hendriks, Bart S., et al.. (2004). Parsing ERK Activation Reveals Quantitatively Equivalent Contributions from Epidermal Growth Factor Receptor and HER2 in Human Mammary Epithelial Cells. Journal of Biological Chemistry. 280(7). 6157–6169. 61 indexed citations

19.

Hendriks, Bart S., Lee K. Opresko, H Wiley, & Douglas A. Lauffenburger. (2003). Coregulation of epidermal growth factor receptor/human epidermal growth factor receptor 2 (HER2) levels and locations: quantitative analysis of HER2 overexpression effects.. PubMed. 63(5). 1130–7. 114 indexed citations

20.

Hendriks, Bart S. & Ernst Reichmann. (2002). Wnt signaling: A complex issue. Biological Research. 35(2). 277–86. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact